Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Respiratory Infection Bacterial Clear all
Withdrawn No phase listed Observational

Reduced Ventilator-Free Days and Bacterial Colonization of Sub-Glottic Secretions

NCT02311296
View directory record Official record
Conditions
Pneumonia
Interventions
Not listed
Lead sponsor
University of Tennessee, Chattanooga
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study)

NCT05037851
View directory record Official record
Conditions
Pulmonary Aspergillosis
Interventions
Opelconazole, Standard of Care
Drug
Lead sponsor
Pulmocide Ltd
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 23, 2026, 1:59 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Cystic Fibrosis

NCT01379040
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Cystic Fibrosis patients
Other
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2014 · Synced Jul 23, 2026, 1:59 PM EDT
Terminated Not applicable Interventional Results available

Pediatric Helmet CPAP Pilot Study

NCT04764929
View directory record Official record
Conditions
Bronchiolitis, Viral, Pneumonia, Viral, Pneumonia, Bacterial
Interventions
Helmet CPAP
Device
Lead sponsor
Columbia University
Other
Eligibility
1 Month to 5 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2024 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Results available

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

NCT00112359
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI 75 mg three times a day (TID), Placebo three times a day (TID)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
40
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2011 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents

NCT01629589
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis, Whooping Cough
Interventions
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 12 Years
Enrollment
423 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
8
States / cities
Sacramento, California • Bardstown, Kentucky • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2016 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

NCT00347958
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tetanus-diphtheria-acellular pertussis (Tdap) vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 69 Years
Enrollment
545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
4
States / cities
Jonesboro, Arkansas • Bossier City, Louisiana • University Heights, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

NCT00467519
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis), DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
1,045 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents

NCT01424644
View directory record Official record
Conditions
Meningococcal Meningitis
Interventions
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine, MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine
Biological
Lead sponsor
Novartis
Industry
Eligibility
11 Years to 18 Years
Enrollment
801 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
17
States / cities
Birmingham, Alabama • Fremont, California • Madera, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 1 Interventional

Escalating Multiple-Dose Safety and Tolerance of WR 6026 Hydrochloride in HIV-Infected Subjects

NCT00000740
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Sitamaquine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1993
U.S. locations
2
States / cities
Indianapolis, Indiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 23, 2026, 1:59 PM EDT
Completed No phase listed Observational

Pharmacodynamic Parameters of Two Different Doses of Cefepime

NCT00177736
View directory record Official record
Conditions
Infection, Bacteremia, Pneumonia
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 12, 2007 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

NCT01530763
View directory record Official record
Conditions
Infections, Community Acquired Pneumonia
Interventions
Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
2 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Long Beach, California • Oakland, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2015 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bacterial Composition and Immune Responses in the Nose and Oropharynx During Influenza Infection

NCT02597647
View directory record Official record
Conditions
Influenza
Interventions
LAIV, Saline
Biological · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 64 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2019 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

NCT01429259
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions
meropenem
Drug
Lead sponsor
Joseph Kuti
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2018 · Synced Jul 23, 2026, 1:59 PM EDT
Terminated Phase 3 Interventional

Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa

NCT03409679
View directory record Official record
Conditions
Pneumonia
Interventions
Murepavadin, Two anti-pseudomonal antibiotics
Drug
Lead sponsor
Polyphor Ltd.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • Springfield, Missouri • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 2 Interventional

A Study to Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

NCT00000811
View directory record Official record
Conditions
Bacterial Infections, Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Azithromycin, Atovaquone, Sulfamethoxazole-Trimethoprim
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 18 Months
Enrollment
690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • La Jolla, California + 46 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 3 Interventional

A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults

NCT00643409
View directory record Official record
Conditions
Maxillary Sinusitis
Interventions
azithromycin SR (Zithromax; compound: CP-62,993), placebo, levofloxacin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
59
States / cities
Alabaster, Alabama • Birmingham, Alabama • Hueytown, Alabama + 37 more
Source: ClinicalTrials.gov public record
Updated May 10, 2011 · Synced Jul 23, 2026, 1:59 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years

NCT00346073
View directory record Official record
Conditions
Acellular Pertussis, Diphtheria, Tetanus
Interventions
Boostrix™, ADACEL®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 64 Years
Enrollment
2,337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
42
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Jul 23, 2026, 1:59 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

NCT02663674
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Fluconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Jul 23, 2026, 1:59 PM EDT
Withdrawn No phase listed Observational

UARK 2009-99 A Non-interventional Observational Study of Infectious Complications in Cancer Patients

NCT01622595
View directory record Official record
Conditions
Aspergillosis, Candidemia, C. Difficile
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2015 · Synced Jul 23, 2026, 1:59 PM EDT
Completed No phase listed Observational

Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia

NCT03996967
View directory record Official record
Conditions
Pneumonia, Bacterial, Viral Infection, Clinical Pneumonia, Plasmodium Falciparum Malaria, Malaria, Infections, Respiratory
Interventions
Not listed
Lead sponsor
Boston University
Other
Eligibility
2 Months to 5 Years
Enrollment
837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Jul 23, 2026, 1:59 PM EDT
Completed No phase listed Observational

Legionnaires' Effect on Smell

NCT03321786
View directory record Official record
Conditions
Legionnaires' Disease
Interventions
The University of Pennsylvania Smell Identification Test (UPSIT)
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Timeline
2017 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2024 · Synced Jul 23, 2026, 1:59 PM EDT